Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor α blockade

Abstract

Anaemia of chronic disease (ACD) is a common feature of active rheumatoid arthritis (RA). Inflammatory cytokines, particularly tumour necrosis factor α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6), are thought to contribute to the pathogenesis of ACD, possibly by inhibiting erythropoietin (EPO) production. In this study, we examined the in vivo effects of TNF-α blockade with a chimeric monoclonal antibody, cA2, on erythropoiesis in RA patients with ACD. Administration of cA2 led to a dose-dependent increase in haemoglobin levels compared to placebo and these changes were accompanied by a reduction in both EPO and IL-6 levels. The data support the notion that TNF-α is important in the causation of ACD, but suggest a mechanism independent of EPO suppression. Instead, TNF-α may act directly on bone marrow red cell precursors.